Benefits of AbISCOŽ adjuvants

Research immunologists, antibody product and service companies, as well as vaccine developers, all share a common need for modern, high performance adjuvants. Isconova's two ready-to-use AbISCOŽ adjuvant formulations meet this need. AbISCOŽ-100 for mice and other particularly sensitive animals and AbISCOŽ-300 a cost-effective preparation for use in larger animals and non-sensitive animals.

Benefits of AbISCOŽ adjuvants include ...

• Very well proven with low risk
• High quality immune response
• Highly efficient plus lower doses
• Non-toxic and free from side-effects
• Broad, general use
• Simple-to-use

End-users simply mix AbISCOŽ adjuvants with the antigen of their choice in solution and inject both together. This AbISCOŽ/antigen mixture makes an excellent formulation for immunizing a wide range of animals with high titers.

Very well proven with low risk

Documented in over 450 publications. ISCOM technology-based animal vaccines already registered. Human vaccine clinical trials ongoing.

High quality immune response

AbISCOŽ adjuvants generates a balanced immune response with both Th1 and Th2 characteristics. This generates all classes and subclasses of antibodies, as well as potent cellular responses, e.g. CTL. The response is initiated in draining lymph nodes but is efficiently relocated to the spleen, which makes it particularly suitable for generating monoclonal antibodies as well.

Highly efficient plus lower doses

After booster, antibody responses are within or higher than those induced by Freund’s complete/incomplete. Antigen dose can be substantially reduced.

Non-toxic and free from side-effects

Adjuvants based on ISCOM technology are inherently safe. Moreover, the development of commercially-approved vaccines has further refined the technology. Efficient, safe and well-tolerated formulations are the hallmarks of AbISCOŽ adjuvants. Today, they fulfil all contemporary ethical considerations.

Broad, general use

ISCOM technology and AbISCOŽ adjuvants is proven for a huge variety of antigens from large glycoproteins such as gp340 from Epstein-Barr virus (a 340 kD antigen consisting of 80% carbohydrates) down to carrier-conjugated synthetic peptides and small haptens such as biotin. Animals used in the studies and trials have been typical laboratory animals, as well as ruminants, birds, fish, monkeys and primates.

Simple-to-use

Compared to many adjuvant formulations that need to be emulsified, or where the antigen needs to be adsorbed, AbISCO adjuvants are extremely simple to use. Just add an appropriate amount of adjuvant to the antigen solution, mix the two by handshaking, and the formulation is ready to inject.